Middle East & Africa Ophthalmic Drugs Market Size & Outlook

The ophthalmic drugs market in Middle East & Africa is expected to reach a projected revenue of US$ 2,237.0 million by 2033. A compound annual growth rate of 7.6% is expected of Middle East & Africa ophthalmic drugs market from 2026 to 2033.
Revenue, 2025 (US$M)
$1,244.9
Forecast, 2033 (US$M)
$2,237.0
CAGR, 2026 - 2033
7.6%
Report Coverage
Middle East & Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Middle East & Africa ophthalmic drugs market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

MEA ophthalmic drugs market highlights

  • The MEA ophthalmic drugs market generated a revenue of USD 1,244.9 million in 2025.
  • The market is expected to grow at a CAGR of 7.6% from 2026 to 2033.
  • In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2025.
  • Anti-VEGF agents is the most lucrative drug class segment registering the fastest growth during the forecast period.
  • Country-wise, South Africa is expected to register the highest CAGR from 2026 to 2033.


MEA data book summary

Market revenue in 2025USD 1,244.9 million
Market revenue in 2033USD 2,237.0 million
Growth rate7.6% (CAGR from 2026 to 2033)
Largest segmentAnti-vegf agents
Fastest growing segmentAnti-VEGF agents
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationAnti-VEGF agents, Anti-glaucoma, Anti-inflammatory, Anti-Allergy
Key market players worldwidePfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc


Other key industry trends

  • In terms of revenue, MEA region accounted for 3.0% of the global ophthalmic drugs market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 16,421.5 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Ophthalmic Drugs Market Companies

Name Profile # Employees HQ Website
Nicox SA Share from reverse split View profile 29 Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, France, 06410 https://www.nicox.com
Coherus BioSciences Inc View profile 306 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, United States, 94065 https://www.coherus.com
Genentech View profile 10001+ South San Francisco, California, United States, North America http://gene.com
Bausch Health Companies Inc View profile 20270 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 https://www.bauschhealth.com
Regeneron Pharmaceuticals Inc View profile 13450 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 https://www.regeneron.com
Bayer AG View profile 99723 Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 https://www.bayer.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Alcon Inc View profile 25315 Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, Switzerland, 1214 https://www.alcon.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

Middle East & Africa ophthalmic drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.


Anti-vegf agents was the largest segment with a revenue share of 37.83% in 2025. Horizon Databook has segmented the Middle East & Africa ophthalmic drugs market based on anti-vegf agents, anti-glaucoma, anti-inflammatory, anti-allergy covering the revenue growth of each sub-segment from 2021 to 2033.


Countries in the Middle East & Africa (MEA) such as South Africa, Saudi Arabia, and the UAE are prospering economies. The market in this region is driven by the high prevalence of dry eye disease, rise in consumer awareness, and improvements in healthcare infrastructure.

Thus, MEA is a largely untapped market for dry eye treatment drugs, with the presence of lucrative opportunities for players. Economic development witnessed in emerging markets, such as South Africa, and high unmet healthcare needs are some of the primary factors driving the growth of this market. There is a high prevalence of dry eye disease in this region.

Reasons to subscribe to Middle East & Africa ophthalmic drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa ophthalmic drugs market databook

  • Our clientele includes a mix of ophthalmic drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa ophthalmic drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa ophthalmic drugs market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA ophthalmic drugs market size, by country, 2021-2033 (US$M)

Middle East & Africa Ophthalmic Drugs Market Outlook Share, 2025 & 2033 (US$M)

MEA ophthalmic drugs market size, by country, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online